Clin Drug Invest. 2004;24(12):695-717. Finally, subcutaneous insulin aspart every 1 or 2 hours was a well tolerated and cost-effective alternative to a standard intravenous protocol of regular ...

The sharp movement in the early deals was seen after the company announced that it had filed its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drug Controller General of India.

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ...

Drugmaker Wockhardt has approached the Drug Controller General of India (DCGI) seeking approvals for its fast-acting insulin analog, Aspart injection. The company’s Aspart insulin injection ...

Wockhardt has filed for marketing approval of its fast-acting insulin analog, Aspart injection, with the DCGI in India. This move aims to address the growing diabetes epidemic and provide patients ...

In addition to the publications reviewed, evidence was also found to support the use of insulin aspart in combination therapy and areas currently ‘off-label´ such as pregnancy and/or ...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark for expanded functionality of the company’s InPen™ smart 2 insulin pen for multiple ...

"At the thought of the title, my eyes fill with tears. I don't know if I am prepared for the... "I made the wrong tire choice, I put the medium behind and should have opted for the soft. SBK? The ...